Abstract
Aims This study investigates the consumption of paracetamol and the risk of potential drug-drug interactions and assesses the clinical impact hereof in patients admitted to a department of geriatric medicine. Methods A retrospective and longitudinal study was conducted in patients who had been receiving paracetamol upon or during hospitalization. The hospital files of the included patients were reviewed, including documentation of concomitant medications, diagnoses, biochemical values, and adverse incidents during admission. These parameters were used as a clinical follow-up when assessing a clinical probability impact of the identified drug-drug interactions. Results In total, 104 patients were admitted during the study period. 91 (87.5%) of these (mean age 86 years) received a prescription or were treated with paracetamol. Of these, 10% were evaluated as being at risk of potential drug-drug interactions with paracetamol. Seven of the potential drug-drug interactions were related to treatments with warfarin, one with valsartan and one with phenytoin. Of the nine patients at risk, six did experience either abnormal biochemical values or potential related clinical incidents. Four patients experienced increased INR (range 3.2–4.6), of which one patient suffered from anaemia and one with hematemesis. Two patients experienced increased ALAT/ASAT (55/42 U/I and 87/51 U/I, both females). One experienced hypertension. Conclusion A large majority of the patients in this study received treatment with paracetamol. Six patients were evaluated as having abnormal biochemical values or were experiencing clinical incidents during their hospitalization potentially related to the identified potential drug-drug interactions.
Highlights
Aims. is study investigates the consumption of paracetamol and the risk of potential drug-drug interactions and assesses the clinical impact hereof in patients admitted to a department of geriatric medicine
Patients are often underrepresented or not included in clinical trials [10], and patients admitted to departments of geriatric medicine are assumed to be more frail and in greater risk of adverse events as they often are treated with concomitant medication due to associated diseases [11, 12]. ese patients are often more vulnerable due to age-related changes in pharmacokinetics and pharmacodynamics [13]. is may lead to an increased risk of acquiring potential toxicity and drug-drug interactions (DDIs) [10, 12]
One patient was at risk of a pDDI with paracetamol and phenytoin. e last patient was at risk of a pDDI with paracetamol and valsartan
Summary
Is study investigates the consumption of paracetamol and the risk of potential drug-drug interactions and assesses the clinical impact hereof in patients admitted to a department of geriatric medicine. Six patients were evaluated as having abnormal biochemical values or were experiencing clinical incidents during their hospitalization potentially related to the identified potential drug-drug interactions. Is results in higher concentrations of paracetamol with increased age and elderly female patients [14]. Despite these findings, recommendation for reducing the maximum daily dosage (4 grams) in elderly patients has not been assessed to be necessary [2, 8, 15]. Is can result in increased concentration of the S-isomer, which is five times as potent as the R-isomer [21, 24,25,26]
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
